Chiesi patents expiration
1. Bethkis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939502 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Jun, 2022
(1 year, 10 months ago) | |
| US6987094 | CHIESI | Optimized formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 7 months ago) | |
| US7696178 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 7 months ago) | |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 12 October, 2012
Treatment: Management of cystic fibrosis patients
Dosage: SOLUTION;INHALATION
BETHKIS family patents
2. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
3. Cardene In 0.86% Sodium Chloride In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
4. Cardene In 4.8% Dextrose In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER family patents
5. Cardene In 5.0% Dextrose In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER family patents
6. Cleviprex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5739152 | CHIESI | Pharmaceutical emulsion |
Apr, 2015
(9 years ago) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2013 |
Drugs and Companies using CLEVIDIPINE ingredient
NCE-1 date: 01 August, 2012
Market Authorisation Date: 01 August, 2008
Treatment: Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable
Dosage: EMULSION;INTRAVENOUS
CLEVIPREX family patents
7. Ferriprox patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7049328 | CHIESI | Use for deferiprone |
Jun, 2021
(2 years ago) | |
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(5 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11723874 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-419) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-418) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
Drugs and Companies using DEFERIPRONE ingredient
NCE-1 date: 15 October, 2015
Market Authorisation Date: 20 April, 2018
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION;ORAL; TABLET;ORAL
FERRIPROX family patents
8. Kengreal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6114313 | CHIESI | Pharmaceutical compositions for freeze drying |
Dec, 2018
(5 years ago) | |
| US6130208 | CHIESI | Formulation containing a nucleotide analogue |
Jun, 2023
(9 months ago) | |
| US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(5 years from now) | |
| US8759316 | CHIESI | Maintenance of platelet inhibition during antiplatelet therapy |
May, 2029
(5 years from now) | |
| US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(6 years from now) | |
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(8 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
9. Mycapssa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US10238709 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11338011 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11510963 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11052126 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US10695397 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
MYCAPSSA family patents
10. Zyflo Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6183778 | CHIESI | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
Sep, 2013
(10 years ago) | |
Drugs and Companies using ZILEUTON ingredient
Market Authorisation Date: 30 May, 2007
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ZYFLO CR family patents